ExcepGen

About ExcepGen

ExcepGen is a company focused on unlocking more tolerable RNA medicines by addressing the cellular response to nucleic acids. Their mission is to improve human health through innovative RNA-based solutions that dampen excessive innate immune responses, leveraging foundational principles of biology for significant impact.

Products & Services

RNAx Platform:An mRNA-encoded protein that modifies cellular responses to RNA and lipid nanoparticles (LNPs) by reducing overactive innate immune responses.

Self-amplifying mRNA Vaccines:A core initiative focused on developing self-amplifying mRNA vaccines.

mRNA Vaccines:General development of mRNA vaccines as part of core initiatives.

Specialties

RNA Medicines mRNA Vaccines Nucleic Acid Vaccines Innate Immune Response Modulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2023-08-24 FD: 2023-08-24	3 investors

Seed Latest

2023-08-24

$4.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas Folliard

Chief Executive Officer & Co-founder

B

Barbara Mertins

Chief Scientific Officer & Co-founder

K

Katherine Barcay

Chief Operating Officer

J

Jason Wojcechowskyj

Director of Vaccines

I

Imre Mäger

Head Of Research And Development

P

Pragya Mukherjee

Scientist, R&D

View 3 more team members with Pro

Unlock Full Team Directory

Recent News

ExcepGen Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised